Company profile
Genedrive
The Genedrive molecular diagnostic system has been developed as an affordable next generation genotyping and sequence analysis device, providing rapid detection in approximately 45-75 minutes depending on the test.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
MR04 | Transaction MzUxNTE0NDcwOGFkaXF6a2N4 | Paper/PDF filed
Published 17 Apr 2026 00:02
RESOLUTIONS | Transaction WUVZRkhYT0hhZGlxemtjeA | Paper/PDF filed
Published 07 Apr 2026 23:15
SH01 | Transaction MzUxMjUyMjI2MmFkaXF6a2N4 | Paper/PDF filed
Published 07 Apr 2026 22:48
Last confirmation statement made up date
Last accounts made up date
TM01 | Transaction MzQzMTg4NDk3NGFkaXF6a2N4
Published 12 Aug 2024 19:51
Company registered at Companies House
1 Apr 2025 to 31 Mar 2026
The DEVOTE programme is helping to bring cutting-edge genetic testing into everyday healthcare in Greater Manchester. By combining expertise from universities, hospitals, and businesses, it has already started improving patient care by making genetic testing a routine part of diagnosis and treatment. The next phase of DEVOTE will continue working with ind...
1 Apr 2023 to 31 Mar 2025
A biomarker is a chemical or signal which can be measured from the human body to help to diagnose disease or predict future health states. Biomarkers are commonly used in healthcare to guide patient management, but there is a major translational bottleneck between the discovery of a clinically relevant biomarker and its implementation in routine practice ...
1 Jun 2018 to 30 Nov 2019
Currently there are limited Point-of-Care (PoC)-applicable sample processing methods needed to recover infectious disease targets from clinical samples prior to molecular diagnostic testing. This means analysis is restricted to centralised laboratory facilities and this significantly impacts time to result and subsequent treatment, and cost to the healthc...
1 Dec 2017 to 29 Feb 2020
Currently there are no suitable independent PoC methods for processing patient blood samples to provide plasma for medical diagnostic tests. This means analysis is restricted to centralised laboratory facilities and this significantly impacts time to result and subsequent treatment, and cost to the healthcare provider. This project seeks to capitalise on ...
